Amgen enlists Entera in a drug discovery pact; Boehringer brings out the budget ax

Amgen has handed a “modest” tech transfer fee over to Entera $ENTX to get them started on a discovery pact focused on inflammatory diseases, plus other ailments. Entera could also get up to $270 million in milestones for the pact with Amgen, designed to get the Israeli company to use its platform tech to “develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has an option to select up to two additional programs to include in the collaboration.”

→ Germany’s Boehringer Ingelheim is moving to ax roughly 300 staffers in France, according to Reuters. The move comes after a 2017 asset swap and the company says it is designed to concentrate efforts in the country around Lyon.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->